EUVIMEDEUVIMED entdecken
Crossref

Switch to faricimab in various retinal diseases: real-world data

Eitan Kaplan, Ori Segal, Elad Moisseiev, GIlad Allon

International Ophthalmology · 02.05.2026 · 46 (1)

DOI: 10.1007/s10792-026-04092-w ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Ophthalmology, online erschienen am 02.05.2026. Verfasst von Eitan Kaplan und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Ophthalmology, Meir Medical Center, Tchernichovsky 59, Kfar Saba, Israel. Hauptthemen laut MEDLINE: Visual Acuity, Retinal Diseases, Drug Substitution. Die Arbeit nennt 21 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

OBJECTIVE: To evaluate the efficacy of faricimab in various retinal conditions in previously treated patients. METHODS: This study included patients who received at least three faricimab injections at a large medical center between April 2023 and October 2024, all of whom were not naive to treatment. RESULTS: A total of 242 eyes from 219 patients were included in the analysis. The diagnoses were: 139 eyes with neovascular age-related macular degeneration (NVAMD), 63 eyes with diabetic macular edema (DME), 24 eyes with polypoidal choroidal vasculopathy (PCV), 5 eyes with choroidal neovascularization (CNV) secondary to central serous retinopathy (CSR), 5 eyes with branch retinal vein occlusion (BRVO) accompanied by cystoid macular edema (CME), 3 eyes with central retinal vein occlusion (CRVO) with CME, and 3 eyes with myopic CNV. Patients had previously received intravitreal injections of medications including bevacizumab, ranibizumab, aflibercept 2 mg, brolucizumab, triamcinolone, and Ozurdex. Following treatment with faricimab, the proportion of eyes with no intraretinal or subretinal fluid increased across all retinal diseases. Additionally, the average central subfield thickness decreased, the interval between injections was extended, and average visual acuity improved in every retinal condition. The average height of the pigment epithelium detachment (PED) decreased in cases of NVAMD and PCV. CONCLUSIONS: Faricimab appears to be effective after the failure of other treatment options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Visual AcuityRetinal DiseasesDrug SubstitutionHumansFemaleIntravitreal InjectionsMaleAngiogenesis InhibitorsAgedRetrospective StudiesTomography, Optical CoherenceMiddle AgedFluorescein AngiographyPolypoidal Choroidal VasculopathyFundus OculiAged, 80 and overAntibodies, Bispecific

Stichwörter der Autor:innen

Age-related macular degenerationChoroidal neovascularizationDiabetic macular edemaFaricimabPolypoidal choroidal vasculopathyVenous occlusive disease

Substanzen

Angiogenesis InhibitorsfaricimabAntibodies, Bispecific

Autor:innen und Institutionen

  • Department of Ophthalmology, Meir Medical Center, Tchernichovsky 59, Kfar Saba, Israel.
  • Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
  • Department of Ophthalmology, Meir Medical Center, Tchernichovsky 59, Kfar Saba, Israel. giladal@clalit.org.il.

Zitieren

APA

Kaplan, E., Segal, O., Moisseiev, E., & Allon, G. (2026). Switch to faricimab in various retinal diseases: real-world data. International Ophthalmology, 46(1). https://doi.org/10.1007/s10792-026-04092-w

Vancouver

Kaplan E, Segal O, Moisseiev E, Allon G. Switch to faricimab in various retinal diseases: real-world data. International Ophthalmology. 2026;46(1). doi:10.1007/s10792-026-04092-w

BibTeX
@article{Kaplan2026,
  author = {Kaplan, Eitan and Segal, Ori and Moisseiev, Elad and Allon, GIlad},
  title = {Switch to faricimab in various retinal diseases: real-world data},
  journal = {International Ophthalmology},
  year = {2026},
  volume = {46},
  number = {1},
  doi = {10.1007/s10792-026-04092-w}
}
Kostenlos starten →